Volume 387, Issue 10021, Pages 866-873 (February 2016) Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial  Prof John F Forbes, MD, Ivana Sestak, PhD, Prof Anthony Howell, MD, Bernardo Bonanni, MD, Prof Nigel Bundred, MD, Christelle Levy, MD, Prof Gunter von Minckwitz, MD, Wolfgang Eiermann, MD, Prof Patrick Neven, MD, Prof Michael Stierer, MD, Chris Holcombe, MD, Prof Robert E Coleman, MD, Prof Louise Jones, PhD, Prof Ian Ellis, MD, Prof Jack Cuzick, PhD  The Lancet  Volume 387, Issue 10021, Pages 866-873 (February 2016) DOI: 10.1016/S0140-6736(15)01129-0 Copyright © 2016 Forbes et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 1 Trial profile ER=oestrogen receptor. DCIS=ductal carcinoma in situ. The Lancet 2016 387, 866-873DOI: (10.1016/S0140-6736(15)01129-0) Copyright © 2016 Forbes et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 2 Recurrence for all breast cancer according to treatment allocation The Lancet 2016 387, 866-873DOI: (10.1016/S0140-6736(15)01129-0) Copyright © 2016 Forbes et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 3 Subgroup analyses for invasive breast cancer by cancer characteristics Numbers do not add to totals because of missing values. The dotted line shows no effect point, and the bold line shows overall treatment effect point. ER=oestrogen receptor. The Lancet 2016 387, 866-873DOI: (10.1016/S0140-6736(15)01129-0) Copyright © 2016 Forbes et al. Open Access article distributed under the terms of CC BY Terms and Conditions